We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals

508 hedge funds and large institutions have $32.9B invested in Regeneron Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 186 increasing their positions, 198 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 43

11% more capital invested

Capital invested by funds: $29.5B → $32.9B (+$3.38B)

5% more funds holding in top 10

Funds holding in top 10: 1920 (+1)

1% less funds holding

Funds holding: 511508 (-3)

6% less repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 198

25% less call options, than puts

Call options by funds: $565M | Put options by funds: $757M

Holders
508
Holders Change
-3
Holders Change %
-0.59%
% of All Funds
13.54%
Holding in Top 10
20
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+5.26%
% of All Funds
0.53%
New
49
Increased
186
Reduced
198
Closed
43
Calls
$565M
Puts
$757M
Net Calls
-$192M
Net Calls Change
+$10.3M
Name Holding Trade Value Shares
Change
Change in
Stake
AG
176
Aperio Group
California
$6.77M +$950K +2,241 +18%
Canada Pension Plan Investment Board
177
Canada Pension Plan Investment Board
Ontario, Canada
$6.73M +$4.08M +9,622 +182%
AAM
178
Advisors Asset Management
Colorado
$6.73M +$589K +1,390 +10%
SAM
179
Shell Asset Management
Netherlands
$6.62M -$1.42M -3,343 -19%
CAM
180
Cypress Asset Management
Texas
$6.59M +$1.2M +2,830 +24%
LPL Financial
181
LPL Financial
California
$6.55M +$615K +1,450 +11%
URS
182
Utah Retirement Systems
Utah
$6.39M +$212K +500 +4%
BAM
183
Burnham Asset Management
New York
$6.39M +$21.2K +50 +0.4%
B
184
Baird
Wisconsin
$6.23M -$2.26M -5,331 -28%
AQR Capital Management
185
AQR Capital Management
Connecticut
$6.16M +$2.11M +4,974 +57%
CTA
186
Chesley Taft & Associates
Illinois
$5.83M
QIM
187
Quest Investment Management
Oregon
$5.67M -$2.13M -5,020 -29%
Nomura Asset Management
188
Nomura Asset Management
Japan
$5.65M +$113K +266 +2%
TCT
189
TIAA CREF Trust
Missouri
$5.24M -$308K -727 -6%
CAM
190
CG Asset Management
New York
$5.1M +$790K +1,865 +20%
BLM
191
Bennett Lawrence Management
New York
$5.08M -$3.05M -7,185 -39%
Janus Henderson Group
192
Janus Henderson Group
United Kingdom
$5.06M
Nisa Investment Advisors
193
Nisa Investment Advisors
Missouri
$5.06M +$84.8K +200 +2%
NCGI
194
Next Century Growth Investors
Minnesota
$4.98M -$111K -263 -2%
BNP Paribas Asset Management
195
BNP Paribas Asset Management
France
$4.98M +$1.52M +3,577 +48%
B
196
BP
United Kingdom
$4.97M -$1.27M -3,000 -21%
CIBC Asset Management
197
CIBC Asset Management
Ontario, Canada
$4.92M +$241K +568 +5%
CB
198
Commerce Bank
Missouri
$4.91M +$5.51K +13 +0.1%
OTPPB
199
Ontario Teachers' Pension Plan Board
Ontario, Canada
$4.9M +$4.6M +10,845 New
Mitsubishi UFJ Asset Management
200
Mitsubishi UFJ Asset Management
Japan
$4.81M -$233K -549 -5%

REGN Hedge Fund Activity: Q1 2015 in Review

508 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2015, worth a combined $32.9B — up 11% from $29.5B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new REGN positions and 43 closed out — a net gain of 6 holders — while 186 added to existing stakes and 198 trimmed.

The largest buyer was Janus Henderson Investors US, adding an estimated $602M. The largest seller was Fidelity Investments, cutting an estimated $287M.

  • 508 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2015, down from 511 in Q4 2014.
  • Funds reported $32.9B of Regeneron Pharmaceuticals stock for Q1 2015, up 11% quarter-over-quarter.
  • 49 funds opened new Regeneron Pharmaceuticals positions in Q1 2015 and 43 closed out, a net change of +6 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q1 2015 was Janus Henderson Investors US, an estimated $602M added.
  • The largest Regeneron Pharmaceuticals seller in Q1 2015 was Fidelity Investments, an estimated $287M sold.

Based on aggregated 13F filings for Q1 2015.